13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001469336
Total reported value
$86.5M
$86.5M
31 檔
101.1%
In Q4 2025, Empery Asset Management, LP's U.S. equity holdings reached a combined market value of $86.5M, distributed across 31 disclosed stock positions.
During Q4 2025, Empery Asset Management, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 31.57% | -7.07% | — | |
| 2 | IMRX | Immuneering CORP - Class A | Stock-Other | 15.52% | — | — | |
| 3 | EMPD | Empery Digital Inc | Stock-Other | 11.80% | -2.87% | — | |
| 4 | ✓ | Imperial Pete Inc | Stock-Other | 10.16% | -4.52% | EXIT | |
| 5 | DTIL | Precision Biosciences Inc | Stock-Other | 8.05% | -5.99% | — | |
| 6 | ADUR | Aduro Clean Technologies Inc | Stock-Other | 5.22% | — | — | |
| 7 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 3.40% | -0.28% | — | |
| 8 | ✓ | Critical Metals CORP | Stock-Other | 3.01% | -1.26% | EXIT | |
| 9 | EOSE | Eos Energy Enterprises Inc | Stock-Other | 2.52% | — | — | |
| 10 | SRZN | Surrozen Inc | Stock-Other | 2.07% | — | — | |
| 11 | TLPH | Talphera Inc | Stock-Other | 1.34% | -0.53% | EXIT | |
| 12 | KZIA | Kazia Therapeutics-spon Adr | Stock-Other | 1.03% | — | — | |
| 13 | PROF | Profound Medical CORP | Stock-Other | 1.00% | — | — | |
| 14 | ✓ | Stock-Other | 0.78% | — | — | ||
| 15 | ✓ | Super League Enterprise Inc | Stock-Other | 0.67% | — | — | |
| 16 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.67% | — | — | |
| 17 | BNTC | Benitec Biopharma Inc | Stock-Other | 0.66% | -0.39% | EXIT | |
| 18 | BCTXZ | Briacell Therapeutics - 30 | Stock-Other | 0.17% | -0.11% | EXIT | |
| 19 | ✓ | Allurion Technologies Inc | Stock-Other | 0.06% | — | — | |
| 20 | TARA | Protara Therapeutic Inc | Stock-Other | 0.06% | — | — | |
| 21 | NTRBW | Nutriband Inc -cw26 | Stock-Other | 0.06% | — | -42.53% | |
| 22 | ✓ | Renatus Tactical Acquis | Stock-Other | 0.04% | +0.01% | — | |
| 23 | ✓ | Neurosense Therapeutics LTD | Stock-Other | 0.03% | -0.01% | -37.25% | |
| 24 | ✓ | Maris Tech LTD | Stock-Other | 0.03% | +0.02% | — | |
| 25 | BNCWW | Cea Industries Inc -cw27 | Stock-Other | 0.02% | -0.01% | — | |
| 26 | NXGLW | Nexgel Inc -cw26 | Stock-Other | 0.02% | -0.01% | — | |
| 27 | MDAIW | Spectral Ai -cw27 | Stock-Other | 0.01% | — | — | |
| 28 | PCTTW | Purecycle Techno-cw26 | Stock-Other | 0.01% | — | -27.67% | |
| 29 | MDCXW | Medicus Pharma LTD -29 | Stock-Other | 0.01% | -0.01% | EXIT | |
| 30 | ✓ | Fgi Industries LTD | Stock-Other | — | +0.01% | -18.12% | |
| 31 | ✓ | Jeffs Brands LTD | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Empery Asset Management, LP reported a total U.S. public equity portfolio value of $86.5M across 31 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XFOR, IMRX, EMPD) accounted for 101.1% of total reported equity market value during Q4 2025.
During Q4 2025, Empery Asset Management, LP's top holdings by market value included XFOR (31.6%)、IMRX (15.5%)、EMPD (11.8%). The largest single position, XFOR, represented 31.6% of total portfolio value.
In Q4 2025, Empery Asset Management, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.